Risk factor | NECP ATP III 2001 [1]* | AHA/NHLBI 2004 [3]† | AHA/NHLBI 2005 [4]† | IDF 2005 [5]** |
---|---|---|---|---|
Central/Abdominal obesity (Waist circumference) | M >102 cm‡ W > 88 cm ‡ | M >102 cm ‡ W > 88 cm ‡ | M ≥ 102 cm §,|| W ≥ 88 cm §,|| | Must have: Central obesity, defined as WC¶ with ethnicity specific values. Europids: male ≥ 94 cm, female ≥ 80 cm plus any two of following 4 factors: |
Blood pressure | ≥130/≥85 mmHg | ≥130/≥85 mmHg | ≥130 mm Hg systolic BP, or ≥ 85 mm Hg diastolic BP, or drug treatment for hypertension | ≥130 mm Hg systolic blood pressure, or ≥ 85 mm Hg diastolic blood pressure, or treatment of previously diagnosed hypertension |
Fasting glucose | 110 mg/dL# | 110 mg/dL** | ≥100 mg/dL or drug treatment for elevated glucose | ≥5.6 mmol/L (100 mg/dL) or previously diagnosed diabetes. If above 5.6 mmol/L, OGTT is strongly recommended but is not necessary to define presence of the syndrome |
Triglycerides | 150 mg/dL | 150 mg/dL | ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated TG†† | ≥1.7 mmol/L (150 mg/dL) or specific treatment for this lipid abnormality |
HDL cholesterol | M <40 mg/dL W <50 mg/dL | M <40 mg/dL W<50 mg/dL | M <40 mg/dL (0.9 mmol/L)†† W <50 mg/dL (1.1 mmol/L)†† or drug treatment for reduced HDL-C‡‡ | M <1.03 mmol/L (40 mg/dL) W <1.29 mmol/L (50 mg/dL) or specific treatment for this lipid abnormality |